Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$377.58 USD

377.58
962,429

+1.21 (0.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $377.57 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks News

Zacks Equity Research

Are ABMD & DXCM Neck and Neck? Let's Take a Closer Look

DexCom (DXCM) scores higher than Abiomed (ABMD) when it comes to current-year revenue projections and fundamentals.

Zacks Equity Research

CONMED's Buffalo Filter Buyout Likely to be Accretive in 2020

CONMED's (CNMD) comprehensive surgical smoke evacuation portfolio lends it a competitive edge in the industry.

Zacks Equity Research

The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo

The Zacks Analyst Blog Highlights: Walgreens Boots, Duke Energy, Stryker, Kinder Morgan and PepsiCo

Zacks Equity Research

Zacks.com featured highlights include: Allison Transmission, Cigna, Celanese and Stryker

Zacks.com featured highlights include: Allison Transmission, Cigna, Celanese and Stryker

Zacks Equity Research

4 GARP Stocks for a Winning Portfolio

Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.

Mark Vickery headshot

Top Stock Reports for Walgreens Boots, Duke Energy & Stryker

Today's Research Daily features new research reports on 16 major stocks, including Walgreens Boots (WBA), Duke Energy (DUK) and Stryker (SYK).

Mark Vickery headshot

Top Research Reports for Oracle, McDonald's & 3M

Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), McDonald's (MCD) and 3M (MMM).

Zacks Equity Research

Thermo Fisher (TMO) Rides on APAC Strength Despite Cost Woes

Thermo Fisher (TMO) is registering a sturdy global footprint with strong growth seen in Asia-Pacific including China.

Zacks Equity Research

Express Scripts & Petco Tie Up, Ease Access to Pet Medicines

Express Scripts' (ESRX) Inside Rx Pets discount card is likely to make pet medicines affordable.

Zacks Equity Research

Boston Scientific's (BSX) $4.2B Buyout to Augment PI Business

Boston Scientific (BSX) continues to expand on the back of its inorganic growth strategy. The latest takeover is expected to boost the PI business.

Zacks Equity Research

Medtronic Moves a Step Ahead With Mazor Robotics Buyout

Medtronic's (MDT) resolve to take over the Israel-based robotic surgical guidance systems company, Mazor Robotics, adheres to its goal to grow in the sphere of robotics spine surgery.

Zacks Equity Research

Edwards Lifesciences' CE Mark for SAPIEN 3 Boosts THVT Arm

Latest CE Mark receipt is expected to fortify Edwards Lifesciences' (EW) position in Europe.

Zacks Equity Research

Hill-Rom Rides on New Products, Asia Pacific Sales Drop

Hill Rom (HRC) sets sights on product innovation. In patient support systems, the company unveils Hill-Rom Envella Air Fluidized Therapy Bed.

Zacks Equity Research

Are WMGI & ARAY Neck and Neck? Let's Take a Closer Look

Wright Medical (WMGI) scores higher than Accuray (ARAY) when it comes to current-year earnings and growth projections.

Zacks Equity Research

GNC Holdings Domestic Revenues Soft, Global Growth Strong

Within same store, GNC Holdings (GNC) disappoints on the domestic franchise locations front. However, its steadily thriving international business is a big boon.

Zacks Equity Research

Will Strong RTG Arm Shape Medtronic's (MDT) Q2 Earnings?

Medtronic (MDT) poised to gain on continued RTG business growth in Q2.

Zacks Equity Research

Merit Medical (MMSI) Completes Cianna Medical Acquisition

Merit Medical (MMSI) is likely to gain traction in the global breast lesion localization market, courtesy of the Cianna Medical acquisition.

Zacks Equity Research

Medidata's Cloud Platform Picked by China's Hengrui, Stock Up

Medidata's (MDSO) cloud-based platform sees immense prospects in APAC.

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

llumina (ILMN) set to take over peer in a $1.2-billion deal, which will strengthen its position in the genomics market.

Zacks Equity Research

Baxter (BAX) Launches Peri-Strips & Tisseel Prima, Shares Up

Baxter's (BAX) diversified surgical portfolio lends it a competitive edge in the MedTech space.

Zacks Equity Research

Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now

Solid fiscal Q4 for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.

Zacks Equity Research

ResMed (RMD) Closes MatrixCare Buyout, Boosts SaaS Line

Post culmination of the transaction, MatrixCare will continue to operate as a standalone business within ResMed's (RMD) SaaS portfolio.

Zacks Equity Research

Haemonetics Strong on Plasma & Hemostasis Management Units

Haemonetics (HAE) sees encouraging growth at the North America Plasma revenues on strong disposables along with growing software revenues.

Zacks Equity Research

NuVasive Porous PEEK Implant OK'd for Use in XLIF Procedure

NuVasive (NUVA) adopts initiatives to boost the U.S. Spinal Hardware unit.

Zacks Equity Research

GNC Holdings (GNC) Q3 Earnings Miss on Soft U.S. Retail

GNC Holdings (GNC) discourages with sluggish domestic retail comps. However, it delivers a strong performance in e-commerce business as well as at International segment.